Generic Name and Formulations:
Sugammadex 100mg/mL; soln for IV inj.
Merck & Co., Inc.
Indications for BRIDION:
To reverse neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery.
Give as single bolus inj over 10 secs. Rocuronium and vecuronium: 4mg/kg if spontaneous recovery of the twitch response has reached 1–2 post-tetanic counts (PTC) with no twitch responses to train-of-four (TOF) stimulation. 2mg/kg if spontaneous recovery has reached the reappearance of the second twitch in response to TOF stimulation. Rocuronium only: 16mg/kg if reversal needed soon (approx. 3mins) after given a single rocuronium 1.2mg/kg dose. Re-administration of neuromuscular blockers post-reversal: see full labeling.
≤17yrs: not established.
Do not use to reverse blockade induced by agents other than rocuronium or vecuronium. Should be administered by trained healthcare providers. Have treatment for anaphylaxis readily available. Maintain ventilation and patent airway; monitor until recovery. Monitor for hemodynamic changes and administer anticholinergic agents (eg, atropine) if significant bradycardia observed. Risk of neuromuscular blockade recurrence; see full labeling. Coagulopathies. Signs of light anesthesia. Severe renal impairment (CrCl <30mL/min), dialysis: not recommended. Hepatic impairment with coagulopathy or severe edema. Elderly. Pregnancy. Nursing mothers.
Recovery could be delayed with concomitant toremifene. May antagonize progestogen; if hormonal contraceptive taken on the same day as Bridion, must use additional non-hormonal contraceptive or back-up method (eg, condom, spermicide) for next 7 days. Increased bleeding risk with anticoagulation therapy, thromboprophylaxis drugs other than heparin and LMWH. May interfere with progesterone assay. Physically incompatible with verapamil, ondansetron, ranitidine.
Modified gamma cyclodextrin.
Vomiting, pain, nausea, hypotension, headache; hypersensitivity, marked bradycardia, increases in aPTT and PT/INR.
Single-dose vials (2mL, 5mL)—10
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|